• News
  • Catch-up: How do pharma companies support MDG...
News - published on 24 Jun 2015

Catch-up: How do pharma companies support MDG5?

Catch-up with the web discussion co-convened by the Access to Medicine Foundation, the UN Foundation and Family Planning 2020 about how pharmaceutical companies’ are improving access to maternal health and contraception. The discussion centers on a landscape study recently published by the Access to Medicine Foundation.

Co-convened by the UN Foundation, Family Planning 2020 and the Access to Medicine Foundation, the webinar centers on the first landscape study of pharmaceutical companies’ commitments and initiatives to MDG 5: to help improve access to maternal health and contraception. It was published by the Access to Medicine Foundation earlier this year.

As we look toward the launch of the Sustainable Development Goals later this year, rigorous monitoring and assessment of these initiatives will be crucial for identifying what works and what needs to be adapted, says Jayasree K. Iyer, Head of Research at the Access to Medicine Foundation.

Speakers

00:00: Natalie Africa, Senior Director, Private Sector Engagement, Every Woman Every Child, United Nations Foundation

07:57: Beth Schlachter, Executive Director, Family Planning

25:44: Jayasree K. Iyer, Head of Research, Access to Medicine

38:35: Peter Stevenson, Vice President for Portfolio Management, Global Established Pharmaceutical Division, Pfizer

46:06: Venkatesh Iyer, Director of Corporate Strategy, Famy Care Ltd.

01:02:16: Priya Agrawal, Executive Director, Merck for Mothers

01:13:38: Q&A

Partnerships for MDG 5

The UN Foundation’s Every Woman Every Child movement and Family Planning 2020 partnership mobilize stakeholders from all sectors, including the pharmaceutical industry, to commit to and work towards achieving the goals set out in MDG 5. The Access to Medicine Foundation tracks how 20 of the world’s largest pharmaceutical companies address access to medicine for 47 high-burden diseases in 106 developing countries.


Learn more

View our detailed overview of each company’s performance in the Index, including breakdowns of their product portfolios and R&D pipelines.